Sequencing Therapies for Relapsed Refractory Multiple Myeloma: Bispecifics or CAR T-cell Therapy

Opinion
Video

Panelists discuss how to optimize the sequencing of bispecific antibodies and CAR T-cell therapies in relapsed/refractory multiple myeloma, considering factors such as patient characteristics, disease burden, and the unique advantages of each approach to maximize treatment efficacy and patient outcomes.

Recent Videos
4 experts in this video
4 experts in this video
5 experts are featured in this series
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
5 experts are featured in this series
Related Content